Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 779

1.

Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.

Bolli R, Hare JM, Henry TD, Lenneman CG, March KL, Miller K, Pepine CJ, Perin EC, Traverse JH, Willerson JT, Yang PC, Gee AP, Lima JA, Moyé L, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2018 Jul;201:54-62. doi: 10.1016/j.ahj.2018.02.009. Epub 2018 Apr 4.

PMID:
29910056
2.

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure).

Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2018 Jun 8;122(12):1703-1715. doi: 10.1161/CIRCRESAHA.118.312978. Epub 2018 Apr 27.

PMID:
29703749
3.

Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.

Marian AJ, Tan Y, Li L, Chang J, Syrris P, Hessabi M, Rahbar MH, Willerson JT, Cheong BY, Liu CY, Kleiman NS, Bluemke DA, Nagueh SF.

Circ Res. 2018 Apr 13;122(8):1109-1118. doi: 10.1161/CIRCRESAHA.117.312647. Epub 2018 Mar 14.

PMID:
29540445
4.

Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1.

Woodside DG, Tanifum EA, Ghaghada KB, Biediger RJ, Caivano AR, Starosolski ZA, Khounlo S, Bhayana S, Abbasi S, Craft JW Jr, Maxwell DS, Patel C, Stupin IV, Bakthavatsalam D, Market RV, Willerson JT, Dixon RAF, Vanderslice P, Annapragada AV.

Sci Rep. 2018 Feb 27;8(1):3733. doi: 10.1038/s41598-018-21893-x.

5.

Magnetic Resonance Imaging-Based Screening Study in a General Population of Adolescents.

Angelini P, Cheong BY, Lenge De Rosen VV, Lopez JA, Uribe C, Masso AH, Ali SW, Davis BR, Muthupillai R, Willerson JT.

J Am Coll Cardiol. 2018 Feb 6;71(5):579-580. doi: 10.1016/j.jacc.2017.11.051. No abstract available.

PMID:
29406865
6.

Global Overview of the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) Recommendations: A Comprehensive Series of Challenges and Priorities of Cardiovascular Regenerative Medicine.

Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Pinto FJ, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS Writing Group.

Circ Res. 2018 Jan 19;122(2):199-201. doi: 10.1161/CIRCRESAHA.117.312099. No abstract available.

PMID:
29348246
7.

Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies.

Auguste G, Gurha P, Lombardi R, Coarfa C, Willerson JT, Marian AJ.

Circ Res. 2018 Mar 2;122(5):678-692. doi: 10.1161/CIRCRESAHA.117.312052. Epub 2018 Jan 9.

PMID:
29317431
8.

TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Chugh A, Yang PC, Zhao DXM, Ellis SG, Forder JR, Perin EC, Penn MS, Hatzopoulos AK, Chambers JC, Baran KW, Raveendran G, Gee AP, Taylor DA, Moyé L, Ebert RF, Simari RD.

Circ Res. 2018 Feb 2;122(3):479-488. doi: 10.1161/CIRCRESAHA.117.311466. Epub 2017 Dec 5.

PMID:
29208679
9.
10.

Distinct Cellular Basis for Early Cardiac Arrhythmias, the Cardinal Manifestation of Arrhythmogenic Cardiomyopathy, and the Skin Phenotype of Cardiocutaneous Syndromes.

Karmouch J, Zhou QQ, Miyake CY, Lombardi R, Kretzschmar K, Bannier-Hélaouët M, Clevers H, Wehrens XHT, Willerson JT, Marian AJ.

Circ Res. 2017 Dec 8;121(12):1346-1359. doi: 10.1161/CIRCRESAHA.117.311876. Epub 2017 Oct 10.

PMID:
29018034
11.

Hippo pathway deficiency reverses systolic heart failure after infarction.

Leach JP, Heallen T, Zhang M, Rahmani M, Morikawa Y, Hill MC, Segura A, Willerson JT, Martin JF.

Nature. 2017 Oct 12;550(7675):260-264. doi: 10.1038/nature24045. Epub 2017 Oct 4.

12.

Direct Stimulation of Cardiogenesis: A New Paradigm for Treating Heart Disease.

Martin JF, Perin EC, Willerson JT.

Circ Res. 2017 Jun 23;121(1):13-15. doi: 10.1161/CIRCRESAHA.117.311062. No abstract available.

13.

Global position paper on cardiovascular regenerative medicine.

Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) Writing Group; Authors/Task Force Members. Chairpersons; Basic Research Subcommittee; Translational Research Subcommittee; Challenges of Cardiovascular Regenerative Medicine Subcommittee; Tissue Engineering Subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee; Clinical Trials Subcommittee; Regulatory and funding strategies subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee.

Eur Heart J. 2017 Sep 1;38(33):2532-2546. doi: 10.1093/eurheartj/ehx248. No abstract available.

14.

The Texas Heart Institute: Part 2-Working Toward the Next Breakthrough in Cardiovascular Medicine.

Willerson JT.

Circ Res. 2017 May 12;120(10):1548-1550. doi: 10.1161/CIRCRESAHA.117.311130. No abstract available.

PMID:
28495990
15.

The Texas Heart Institute: Part 1-An Historical Perspective.

Willerson JT.

Circ Res. 2017 May 12;120(10):1545-1547. doi: 10.1161/CIRCRESAHA.117.310760. No abstract available.

PMID:
28495989
16.

The ubiquitin-proteasome system: A potential therapeutic target for heart failure.

Barac YD, Emrich F, Krutzwakd-Josefson E, Schrepfer S, Sampaio LC, Willerson JT, Robbins RC, Ciechanover A, Mohr FW, Aravot D, Taylor DA.

J Heart Lung Transplant. 2017 Jul;36(7):708-714. doi: 10.1016/j.healun.2017.02.012. Epub 2017 Feb 20. Review.

PMID:
28341100
17.

Fare Thee Well, Dr. Cooley.

Fred HL, Willerson JT.

Tex Heart Inst J. 2017 Feb 1;44(1):3-6. doi: 10.14503/THIJ-17-6232. eCollection 2017 Feb. No abstract available.

18.

A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder.

Li L, Bainbridge MN, Tan Y, Willerson JT, Marian AJ.

Circ Res. 2017 Mar 31;120(7):1084-1090. doi: 10.1161/CIRCRESAHA.116.310559. Epub 2017 Feb 21.

19.

CD133+ Stem Cells in the Treatment of Patients With Refractory Angina.

Willerson JT.

Circ Res. 2017 Feb 17;120(4):602-603. doi: 10.1161/CIRCRESAHA.117.310445. No abstract available.

PMID:
28209787
20.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC, Leeper NJ, Dalman RL, Alexander J, Henry TD, Traverse JH, Pepine CJ, Anderson RD, Berceli S, Willerson JT, Muthupillai R, Gahremanpour A, Raveendran G, Velasquez O, Hare JM, Hernandez Schulman I, Kasi VS, Hiatt WR, Ambale-Venkatesh B, Lima JA, Taylor DA, Resende M, Gee AP, Durett AG, Bloom J, Richman S, G'Sell P, Williams S, Khan F, Gyang Ross E, Santoso MR, Goldman J, Leach D, Handberg E, Cheong B, Piece N, DiFede D, Bruhn-Ding B, Caldwell E, Bettencourt J, Lai D, Piller L, Simpson L, Cohen M, Sayre SL, Vojvodic RW, Moyé L, Ebert RF, Simari RD, Hirsch AT; Cardiovascular Cell Therapy Research Network (CCTRN).

Circulation. 2017 Apr 11;135(15):1417-1428. doi: 10.1161/CIRCULATIONAHA.116.025707. Epub 2017 Feb 16.

Supplemental Content

Loading ...
Support Center